1 / 21

screening for Prostate cancer

screening for Prostate cancer. M Ravanbod Medical oncologist Bushehr – 11/91. A 50 y/o white man comes for check up and wants to discuss about prostate cancer. Negative family history No lower urinary tract symptoms What would you advise?. Most frequent non-skin cancer

artie
Download Presentation

screening for Prostate cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. screening for Prostate cancer M Ravanbod Medical oncologist Bushehr – 11/91

  2. A 50 y/o white man comes for check up and wants to discuss about prostate cancer. • Negative family history • No lower urinary tract symptoms • What would you advise?

  3. Most frequent non-skin cancer • Second leading cause of cancer death • About 250,000 new cases anually • About 34,000 deaths/yr • After peaking in early 1990s about 30% decrease till 2007 • After 2007 at diagnosis 80% confined to prostate ,4% metastatic

  4. Risk factors • Older age • Positive family history • Black race • Median age at diagnosis is 67.

  5. In the US 90% detected by screening • After introduction of PSA lifetime diagnosis doubled ;9% in 1985;16% in 2007 • Great majority of men with a diagnosis of prostate cancer die from other causes • Autopsy data suggests 30% of men>50y and 70% >70y have occult prostate cancer.

  6. SEER registry data • 90,000 prostate cancer 1992-2002 • Death risk from prostate cancer: 8% for well-diff. tumors 26% for poorly-diff. • Death risk from other causes:60%

  7. Screening • The rationale for screening is that early detection and treatment of asymptomatic cancers could extend life, as compared with treatment at the time of clinical diagnosis.

  8. Effective screening requires: - an accurate,reliable,easy to administer test that detects clinically important cancers at a preclinical stage. -availability of effective treatment that results in better outcomes when administered early.

  9. For many years DRE was the primary screening test for prostate cancer • In the late 1980s PSA widely adopted for screening. • There was no evidence that testing reduced the risk of death from prostate cancer

  10. False positive PSA • BPH • prostatitis • Cystitis • Ejaculation • Perineal trauma • Recent urinary tract instrumentation or surgery

  11. False negative • In prostate cancer prevention trial: -15% of men with normal DRE and PSA= 4 had prostate cancer - 9% in nl DRE and PSA< 1

  12. Approaches to improve the diagnostic accuracy of PSA test • Measuring PSA velocity • Free & pr-bound PSA • PSA density • Use of cutoff values for age & race • However,the clinical usefulness of these strategies remains unproved.

  13. ERSPC trial • 7 europian countries • 182,160 men between 50-74y • Prostate cancer 8.2% in screen group vs 4 .8% in control group • Mortality from prostate cancer was 20% lower in screen group, not for 50-54 & 70-74 y

  14. PLCO trial • In US , 76693 men between 55-74 y • PSA & DRE annually for 6 yrs • 22% more cases detected in screen group • Did not show any reduction in overall or prostate cancer mortality

  15. US Preventive Services Task Force • Recently issued a draft recommendation against PSA screening for asymptomatic men, regardless of their age,race or family history • The Task Force concluded that the harms of screening outweigh the benefits.

  16. conclusion • Decision about prostate cancer screening should be based on the preferences of an informed patient.

  17. ACS guidelines • Shared decision making between patient and physician • Age to begin: - average risk :50 (40 in AUA) - high risk (black or 1st degree relative with prostate cancer) : 40-45 (40 in AUA) • Discontinuation of screening: life expectancy <10 yr

  18. Screening tests: PSA , DRE(optional) • Frequency : annual (every other yr if PSA<2.5) • Criteria for biopsy:PSA>4.abnormal DRE. Individualize risk assessment if PSA = 2.5-4

More Related